Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Antibodies directed against tau that are currently in phase 1 or phase 2 trials in AD.


  1. 1.

    Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007).

    Article  Google Scholar 

  2. 2.

    Dam, T. et al. Nat. Med. (2021).

  3. 3.

    Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021).

    Article  Google Scholar 

  4. 4.

    Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019).

    Article  Google Scholar 

  5. 5.

    Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020).

    CAS  Article  Google Scholar 

  6. 6.

    Yanamandra, K. et al. Ann. Clin. Transl. Neurol. 2, 278–288 (2015).

    CAS  Article  Google Scholar 

  7. 7.

    Kim, B., et al. Acta Neuropathol. (2021).

  8. 8.

    Jabbari, E. et al. Ann. Neurol. 84, 485–496 (2018).

    CAS  Article  Google Scholar 

  9. 9.

    Alzforum. (2021).

  10. 10.

    Jabbari, E. et al. Lancet Neurol. 20, 107–116 (2021).

    CAS  Article  Google Scholar 

  11. 11.

    Evans, L.D. et al. Preprint at bioRxiv (2020).

  12. 12.

    Myeku, N. et al. Nat. Med. 22, 46–53 (2016).

    CAS  Article  Google Scholar 

  13. 13.

    Ji, C. & Sigurdsson, E.M. Drugs (2021).

Download references

Author information



Corresponding authors

Correspondence to Edwin Jabbari or Karen E. Duff.

Ethics declarations

Competing interests

E.J. was a study-site sub-investigator in the gosuranemab trial. K.E.D. is a director and scientific board member of Ceracuity.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jabbari, E., Duff, K.E. Tau-targeting antibody therapies: too late, wrong epitope or wrong target?. Nat Med 27, 1341–1342 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing